Skip to main content
SpringerLink
Log in

Gastrointestinal stromal tumors: Diagnosis, therapy and follow-up care in Austria

Gastrointestinale Stromatumoren: Empfehlungen für Diagnose, Behandlung und Nachsorge in Österreich

  • original article
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Summary

Optimal treatment for patients suffering from gastrointestinal stromal tumors (GIST) is based on an interdisciplinary treatment approach. Austrian representatives of Medical and Surgical Oncology, Pathology, Radiology, Nuclear Medicine, Gastroenterology, and Laboratory Medicine issued this manuscript on a consensual base within the context of currently available and published literature. This paper contains guidelines and recommendations for diagnosis, therapy, and follow-up of GIST patients in Austria.

Zusammenfassung

Die interdisziplinäre Behandlung von Gastrointestinalen Stromatumoren ist Grundvoraussetzung für eine adäquate Behandlung dieser seltenen Tumorentität. Österreichische Vertreter aus den Fachdisziplinen der Onkologie, Chirurgie, Pathologie, Radiologie, Nuklearmedizin, Gastroenterologie und Labormedizin verfassten dieses Manuskript konsensuell. Anhand der, bei der Manuskripterstellung verfügbaren und publizierten Fachliteratur, wurden Leitlinien und Empfehlungen für Diagnose, Therapie und Kontrolle von GIST-PatientInnen in Österreich erstellt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol. 2002;33:459–65.

    Article  Google Scholar 

  2. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507–19.

    Article  PubMed  CAS  Google Scholar 

  3. Miettinen M, Virolainen M, Maarit Sarlomo R. Gastrointestinal stromal tumors—value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol. 1995;19:207–16.

    Article  PubMed  CAS  Google Scholar 

  4. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature. 1995;373:347–9.

    Article  PubMed  CAS  Google Scholar 

  5. Kindblom L, Ramotti H, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–69.

    PubMed  CAS  Google Scholar 

  6. Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol. 2000;156(4):1157–63.

    Article  PubMed  CAS  Google Scholar 

  7. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–80.

  8. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.

    Article  PubMed  CAS  Google Scholar 

  9. Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 2009;62(7):613–6.

    Article  PubMed  CAS  Google Scholar 

  10. Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, et al. (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47(10):853–9.

    Article  PubMed  CAS  Google Scholar 

  11. Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133:141–8.

    Article  PubMed  CAS  Google Scholar 

  12. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.

    Article  PubMed  CAS  Google Scholar 

  13. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9.

    Article  PubMed  CAS  Google Scholar 

  14. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer. 2005;103:821–9.

    Article  PubMed  Google Scholar 

  15. Agaimy A, Wünsch PH, Hofstaedter F, Blaszyk H, Rümmele P, Gaumann A, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31:113–20.

    Article  PubMed  Google Scholar 

  16. Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, Saito K, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37:1527–35.

    Article  PubMed  Google Scholar 

  17. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34:1480–91.

    Article  PubMed  Google Scholar 

  18. Janeway KA, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H, et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha- wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007;67:9084–8.

    Article  PubMed  CAS  Google Scholar 

  19. Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol. 2005;29:1373–81.

    Article  PubMed  Google Scholar 

  20. Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol. 2005;27:179–87.

    Article  PubMed  Google Scholar 

  21. Agaimy A, Hartmann A. Hereditary and non-hereditary syndromic gastointestinal stromal tumours. Pathologe. 2010;31:430–7.

    Article  PubMed  CAS  Google Scholar 

  22. Belinsky MG, Skorobogatko YV, Rink L, Pei J, Cai KQ, Vanderveer LA, et al. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2009;48:886–96.

    Article  PubMed  CAS  Google Scholar 

  23. Kleinbaum EP, Lazar AJ, Tamborini E, Mcauliffe JC, Sylvestre PB, Sunnenberg TD, et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer. 2008;122:711–8.

    Article  PubMed  CAS  Google Scholar 

  24. Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol. 2005;23:2735–43.

    Article  PubMed  CAS  Google Scholar 

  25. Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol. 2005;29:1170–6.

    Article  PubMed  Google Scholar 

  26. Maertens O, Prenen H, Debiec-Rychter M, Wozniak A, Sciot R, Pauwels P, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet. 2006;15:1015–23.

    Article  PubMed  CAS  Google Scholar 

  27. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30:90–6.

    Article  PubMed  Google Scholar 

  28. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc. 1999;74:543–52.

    Article  PubMed  CAS  Google Scholar 

  29. Zhang L, Smyrk TC, Young WF, Jr., Stratakis CA, Carney JA. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol. 2010;34:53–64.

    Article  PubMed  Google Scholar 

  30. Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16:79–88.

    Article  PubMed  CAS  Google Scholar 

  31. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.

    Article  PubMed  CAS  Google Scholar 

  32. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477–89.

    Article  PubMed  Google Scholar 

  33. Miettinen M, Sobin LH. Gastrointestinal stromal tumors in the appendix: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2001;25:1433–7.

    Article  PubMed  CAS  Google Scholar 

  34. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52–68.

    Article  PubMed  Google Scholar 

  35. Miettinen M, Monihan JM, Sarlomo-Rikala M, Sarlomo-Rikala M, Kovatich AJ, Carr NJ, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999;23:1109–18.

    Article  PubMed  CAS  Google Scholar 

  36. Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000;13:577–85.

    Article  PubMed  CAS  Google Scholar 

  37. Agaimy A, Wunsch PH. Gastrointestinal stromal tumours: a regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbecks Arch Surg. 2006;391:322–9.

    Article  PubMed  Google Scholar 

  38. Agaimy A, Markl B, Arnholdt H, Terracciano LM, Dirnhofer S, Hartmann A, et al. Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs. Virchows Arch. 2009;455:101–8.

    Article  PubMed  CAS  Google Scholar 

  39. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38(Suppl 5):S37–S38.

    Article  PubMed  Google Scholar 

  40. Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 2006;23:120–129.

    Article  PubMed  Google Scholar 

  41. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8 (Suppl 2):S1–S41.

    PubMed  CAS  Google Scholar 

  42. Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol. 2009;33:218–26.

    Article  PubMed  Google Scholar 

  43. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology. 2005;47:41–7.

    Article  PubMed  CAS  Google Scholar 

  44. Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int. 2006;56:1–9.

    Article  PubMed  CAS  Google Scholar 

  45. Montemurro M, Dirnhofer S, Borner M, Burkhard R, Demartines N, Furrer M, et al. Diagnose und Behandlung von GIST in der Schweiz. Schweizer Med Forum. 2008;8:544–9.

    Google Scholar 

  46. Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus HU. Mutation analysis of GIST: increasing significance for risk assessment and effective targeted therapy. Virchows Arch. 2007;451:743–9.

    Article  PubMed  Google Scholar 

  47. Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 2009;33:437–46.

    Article  PubMed  Google Scholar 

  48. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites, and differential diagnosis. Semin Diagn Pathol. 2006;23:70–83.

    Article  PubMed  Google Scholar 

  49. College of American Pathologists (CAP). Cancer Protocols and checklists—GIST. Available at: www.cap.org.

  50. Dow N, Giblen G, Sobin LH, Miettinen M. Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol. 2006;23:111–9

    Article  PubMed  Google Scholar 

  51. Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol. 2008;21 (Suppl 2):S31–6.

    Article  PubMed  CAS  Google Scholar 

  52. Corless CL, Heinrich MC; Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557–86.

    Article  PubMed  CAS  Google Scholar 

  53. Gustafsson BI, Siddique L, Chan A, Dong M, Drozdov I, Kidd M, et al. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973–2004, and current diagnosis and therapy. Int J Oncol. 2008;33:1121–31.

    PubMed  Google Scholar 

  54. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch. 2010;456:111–27.

    Article  PubMed  Google Scholar 

  55. Casali PG, Blay JY, ESMO/CONTICANET/EUROBONET. Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 (Suppl 5):98–102.

    Article  Google Scholar 

  56. Blackstein ME, Corless CL, Ballman KV, et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase III trial ACOSOG Z9001. Presented at the 2010 Gastrointestinal Cancers Symposium 2010, Orlando, Florida; Abstract No. 6.

  57. Corless CL, Ballman KVC, Antonescu C, et al. American College of Surgeons Oncology Group. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol. 2010;28:15s (suppl; abstr 10006).

    Google Scholar 

  58. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.

    Article  PubMed  Google Scholar 

  59. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.

    Article  PubMed  Google Scholar 

  60. Hohenberger P, Ronellenfitsch U, Oladeji O, Pink D, Ströbel P, Wardelmann E, Reichardt P.Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg. 2010;97:1854–9.

    Article  PubMed  CAS  Google Scholar 

  61. Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045–5.

    Article  PubMed  Google Scholar 

  62. Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol. 2010;3:461–71.

    PubMed  Google Scholar 

  63. Katenkamp D, Katenkamp K. Gastrointestinale Stromatumoren. Diagnose und Malignitätseinschätzung. Chirurg. 2008;79:625–9.

    CAS  Google Scholar 

  64. Dietrich CF, Jenssen C. Evidenzbasierte Einsatzmöglichkeiten der Endosonografie. Z Gastroenterol. 2011;49:599–621.

    Article  PubMed  CAS  Google Scholar 

  65. Akahoshi K, Sumida Y, Matsui N, Oya M, Akinaga R, Kubokawa M, et al. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine-needle aspiration. World J Gastroenterol. 2007;13:2077–82.

    PubMed  Google Scholar 

  66. Fernández-Esparrach G, Sendino O, Solé M, Pellisé M, Colomo L, Pardo A, et al. Endoscopic ultrasound-guided fine-needle aspiration and trucut biopsy in the diagnosis of gastric stromal tumors: a randomized crossover study. Endoscopy. 2010;42:292–9.

    Article  PubMed  Google Scholar 

  67. Dewitt J, Emerson RE, Sherman S, Al-Haddad M, McHenry L, Cote GA, Leblanc JK. Endoscopic ultrasound-guided Trucut biopsy of gastrointestinal mesenchymal tumor. Surg Endosc. 2011;25:2192–202.

    Article  PubMed  Google Scholar 

  68. Philipper M, Hollerbach S, Gabbert HE, Heikaus S, Böcking A, Pomjanski N, et al. Prospective comparison of endoscopic ultrasound-guided fine-needle aspiration and surgical histology in upper gastrointestinal submucosal tumors. Endoscopy. 2010;42:300–5.

    Article  PubMed  CAS  Google Scholar 

  69. Polkowski M, Gerke W, Jarosz D, Nasierowska-Guttmejer A, Rutkowski P, et al. Diagnostic yield and safety of endoscopic ultrasound-guided trucut (corrected) biopsy in patients with gastric submucosal tumors: a prospective study. Endoscopy. 2009;41:329–34.

    Article  PubMed  CAS  Google Scholar 

  70. Persson S, Kindblom LG, Angervall L, Tisell LE. Metastasizing gastric epithelioid leiomyosarcomas (leiomyoblastomas) in young individuals with long-term survival. Cancer. 1992;70:721–32.

    Article  PubMed  CAS  Google Scholar 

  71. Valadão M, de Mello EL, Lourenço L, Vilhena B, Romano S, Castro Ldos S. What is the prognostic significance of metastatic lymph nodes in GIST? Hepatogastroenterology. 2008;55:471–4.

  72. Kingham TP, DeMatteo RP. Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin North Am. 2009;89:217–33.

    Article  PubMed  Google Scholar 

  73. Raut CP, Ashley SW. How I do it: surgical management of gastrointestinal stromal tumors. J Gastrointest Surg. 2008;12:1592–9.

    Article  PubMed  Google Scholar 

  74. Langer C, Schüler P, Becker H, Liersch T. Gastrointestinale Stromatumore aus chirurgischer Sicht. Chirurg. 2008;79:644–9.

    Article  PubMed  CAS  Google Scholar 

  75. Otani Y, Furukawa T, Yoshida M, Saikawa Y, Wada N, Ueda M, et al. Operative indications for relatively small (2–5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery. 2006;139:484–92.

    Article  PubMed  Google Scholar 

  76. Pitsinis V, Khan AZ, Cranshaw I, Allum WH. Single center experience of laparoscopic vs. open resection for gastrointestinal stromal tumors of the stomach. Hepatogastroenterology. 2007;54:606–8.

    PubMed  CAS  Google Scholar 

  77. Alam I, Kheradmand F, Alam S, Jamil A, Wilson I, Hurley M. Laparoscopic management of acutely presenting gastrointestinal stromal tumors: a study of 9 cases and review of literature. J Laparoendosc Adv Surg Tech A. 2007;17:626–33.

    Article  PubMed  Google Scholar 

  78. Privette A, McCahill L, Borrazzo E, Single RM, Zubarik R. Laparoscopic approaches to resection of suspected gastric gastrointestinal stromal tumors based on tumorlocation. Surg Endosc. 2008;22:487–94.

    Article  PubMed  CAS  Google Scholar 

  79. Catena F, Di Battista M, Fusaroli P, Ansaloni L, Di Scioscio V, Santini D et al. Laparoscopic treatment of gastric GIST: report of 21 cases and literature review. J Gastrointest Surg. 2008;12:561–8.

    Article  PubMed  Google Scholar 

  80. Sexton JA, Pierce RA, Halpin VJ, Eagon JC, Hawkins WG, Linehan DC, et al. Laparoscopic gastric resection for gastrointestinal stromal tumors. Surg Endosc. 2008;22:2583–7

    Article  PubMed  Google Scholar 

  81. Silberhumer GR, Hufschmid M, Wrba F, Gyoeri G, Schoppmann S, Tribl B, et al. Surgery for gastrointestinal stromal tumors of the stomach. J Gastrointest Surg. 2009;13:1213–9.

    Article  PubMed  Google Scholar 

  82. Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, Lu D (2009) Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin. 59:145–70.

    Article  PubMed  Google Scholar 

  83. Kamusella PC, Bethke A, Platzek I, Wiggermann P, Wissgott C, Stroszczynski C (2009) Minimalinvasive Therapieoptionen bei Metastasen gastrointestinaler Stromatumoren. Radiologe. 49:1132–5.

    Article  PubMed  CAS  Google Scholar 

  84. Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010;33:11–7.

    Article  PubMed  Google Scholar 

  85. Bale R, Widmann G, Haidu M. Stereotactic Radiofrequency Ablation. Cardiovasc Intervent Radiol Cardiovasc Intervent Radiol. 2011;34:852–6.

    Article  Google Scholar 

  86. Bale R, Widmann G, Stoffner DI. Stereotaxy: breaking the limits of current radiofrequency ablation techniques. Eur J Radiol. 2010;75:32–6.

    Article  PubMed  Google Scholar 

  87. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14–24.

    Article  PubMed  Google Scholar 

  88. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/ adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42–7.

    Article  PubMed  CAS  Google Scholar 

  89. Heinrich MC, Owzar K, Corless CI, Hollis D, Borden EC, Fletcher CDM, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360–7.

    Article  PubMed  CAS  Google Scholar 

  90. Van Den Abbeele AD. The lessons of GIST – PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13(Suppl 2):8–13.

    Article  PubMed  Google Scholar 

  91. Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008;98:27–33.

    Article  PubMed  Google Scholar 

  92. De Matteo RP, Owzar K, Antonescu CR, Maki R, Demetri GD, McCarter M, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. Gastrointestinal Cancers Symposium 2008; Abstract 8.

  93. DeMatteo R, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.

    Article  PubMed  CAS  Google Scholar 

  94. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced GIST comparing interruption vs. continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–13.

    Article  PubMed  CAS  Google Scholar 

  95. Joensuu H, Eriksson M, Sundby Hall K, Hartmann J, Pink D, Schütte J et al. One vs. Three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72.

    Article  PubMed  CAS  Google Scholar 

  96. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–32.

    PubMed  CAS  Google Scholar 

  97. Demetri GD, von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

    Article  PubMed  CAS  Google Scholar 

  98. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5.

    Article  PubMed  CAS  Google Scholar 

  99. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32.

    Article  PubMed  CAS  Google Scholar 

  100. Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.

    Article  PubMed  CAS  Google Scholar 

  101. Van Glabbeke MM, Owzar K, Rankin C Simes J, Crowley J, GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients. J Clin Oncol. 2007;25(18S):10004.

    Google Scholar 

  102. Debiec-Rychter M, Sciot R, Le Cescne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093–103.

    Article  PubMed  CAS  Google Scholar 

  103. Ray-Coquard IL, Bin Bui N, Adenis A, Rios M Sr., Bertucci F, Chabaud S, et al; Groupe Sarcome Francais & Groupe d’Etude des Tumeurs Osseuses (GSF-GETO). Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. J Clin Oncol. 2010;28:15s (suppl; abstr 10032).

    Google Scholar 

  104. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced GIST crossing over to a daily Imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41:1751–7.

    Article  PubMed  CAS  Google Scholar 

  105. Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008;44:501–9.

    Article  PubMed  CAS  Google Scholar 

  106. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, et al. Imatinib plasma levels correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141–7.

    Article  PubMed  CAS  Google Scholar 

  107. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38.

    Article  PubMed  CAS  Google Scholar 

  108. George S, Blay JY, Casali PG, Le Cesne A, Stephanson P, Deprimo SE, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45:1959–68.

    Article  PubMed  CAS  Google Scholar 

  109. Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Pat Anticancer Drug Discov. 2008;3:88–99.

    Article  PubMed  CAS  Google Scholar 

  110. Reichardt P. Novel approaches to imatinib- and sunitinib-resistant GIST. Curr Oncol Rep. 2008;10:344–9.

    Google Scholar 

  111. Cassier PA, Dufresne A, Arifi S, El Sayadi H, Ray-Coquard I, Bringuier PP, et al. Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. Curr Gastroenterol Rep. 2008;10:555–61.

    Article  PubMed  Google Scholar 

  112. Nilsson B, Nilsson O, Ahlmann H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib—and then? Exp Opin Investig Drugs. 2009;18:457–68.

    Article  CAS  Google Scholar 

  113. Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer. 2011;31 (Epub ahead of print).

  114. Demetri GD, Scott A, Benjamin RS, Bui MM, Casper ES, Conrad EU III, et al. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 2.2010). J Natl Compr Canc Netw. 2010;8:630–74.

    PubMed  Google Scholar 

  115. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 (Suppl 5):v98–102.

    Google Scholar 

  116. Pantaleo MA, Di Battista M, Catena F, Astorino M, Saponara M, Di Scioscio V, et al. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol. 2008;134:625–30.

    Google Scholar 

  117. Ruka W, Rutkowski P, Szawlowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, et al. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol. 2009;35:87–91.

    Article  PubMed  CAS  Google Scholar 

  118. Jones RL, McCall J, Adam A, O’Donnell D, Ashley S, Al-Muderis O, et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol. 2010;36:477–82.

    Article  PubMed  CAS  Google Scholar 

  119. Avritscher R, Gupta S. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. Hematol Oncol Clin North Am. 2009;23:129–70.

    Article  PubMed  Google Scholar 

  120. Sleijfer S, Wiemer E, Seynaeve C, Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist. 2007;12:719–26.

    Article  PubMed  CAS  Google Scholar 

  121. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–9.

    Article  PubMed  CAS  Google Scholar 

  122. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64–74.

    Article  PubMed  CAS  Google Scholar 

  123. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.

    Article  PubMed  Google Scholar 

  124. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    CAS  Google Scholar 

  125. Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009;27:3969–74.

    Article  PubMed  CAS  Google Scholar 

  126. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760–4.

    Article  PubMed  Google Scholar 

  127. Sabate E. Adherence to long-term therapies: evidence for action. Geneva, World Health Organization 2003.

  128. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–8.

    Article  PubMed  CAS  Google Scholar 

  129. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–11.

    Article  PubMed  CAS  Google Scholar 

  130. DeMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Medical Care. 2002;40:794–811.

    Article  Google Scholar 

  131. Rosen MA. Use of modified RECIST criteria to improve response assessment in targeted therapies: challenges and opportunities. Cancer Biol Ther. 2010;9:20.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Department of Surgery, General Hospital, Wiener Neustadt, Vienna, Austria

    Evelyne Bareck & Friedrich Längle

  2. Clinical Division of Radiology, Medical University Vienna, Vienna, Austria

    Ahmed Ba-Ssalamah

  3. Clinical Division of Oncology, Department of Internal Medicine I, General Hospital, Medical University Vienna, Vienna, Austria

    Thomas Brodowicz

  4. Department of Internal Medicine 1, Medical University Innsbruck, Innsbruck, Austria

    Wolfgang Eisterer

  5. Clinical Division of Gastroenterology, Department of Internal Medicine, Hospital St. Elisabeth, Vienna, Austria

    Michael Häfner

  6. Clinical Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Christoph Högenauer

  7. LabDia Labordiagnostik GmbH, Vienna, Austria

    Ulrike Kastner

  8. Department of Internal Medicine 4, Hospital Wels, Grieskirchen, Austria

    Thomas Kühr

  9. Clinical Division of Pathology, Medical University of Graz, Graz, Austria

    Bernadette Liegl-Atzwanger

  10. Clinical Division of General Surgery, Department of Surgery, General Hospital, Medical University Vienna, Vienna, Austria

    Sebastian F. Schoppmann

  11. Department of Radiology, Medical University Innsbruck, Innsbruck, Austria

    Gerlig Widmann

  12. Institute of Clinical Pathology, General Hospital, Medical University Vienna, Vienna, Austria

    Fritz Wrba

  13. Department of Surgery, Hospital Herz Jesu, Vienna, Austria

    Johannes Zacherl

  14. Clinical Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Ferdinand Ploner

  15. GIPA, Vienna, Austria

    Evelyne Bareck, Ahmed Ba-Ssalamah, Thomas Brodowicz, Wolfgang Eisterer, Michael Häfner, Christoph Högenauer, Ulrike Kastner, Thomas Kühr, Friedrich Längle, Bernadette Liegl-Atzwanger, Sebastian F. Schoppmann, Gerlig Widmann, Fritz Wrba, Johannes Zacherl & Ferdinand Ploner

Authors
  1. Evelyne Bareck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed Ba-Ssalamah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Brodowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wolfgang Eisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Häfner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christoph Högenauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ulrike Kastner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Thomas Kühr
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Friedrich Längle
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bernadette Liegl-Atzwanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sebastian F. Schoppmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gerlig Widmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Fritz Wrba
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Johannes Zacherl
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ferdinand Ploner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evelyne Bareck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bareck, E., Ba-Ssalamah, A., Brodowicz, T. et al. Gastrointestinal stromal tumors: Diagnosis, therapy and follow-up care in Austria. Wien Med Wochenschr 163, 137–152 (2013). https://doi.org/10.1007/s10354-013-0187-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-013-0187-3

Keywords

Schlüsselwörter

Search

Navigation